Tianjin KMD Bioscience Co., Ltd. is dedicated to becoming a leading provider of therapeutic antibody discovery and related support services. With technology R&D at our core, we deliver high-quality CRO (Contract Research Organization) services to scientists and research institutions worldwide, driving advancement and innovation in medical technology.

As a national high-tech enterprise, we hold certifications as a National Patent Pilot Unit and maintain an ISO 9001:2015 quality management system for our laboratories. We have secured over 30 patents and 4 registered trademarks. Over 90% of KMD Bioscience’s technical team holds master’s degrees or higher. Annually, we provide nearly a thousand technical service consultations, project designs, and deliverables to global research institutions, hospitals, pharmaceutical companies, and biotech firms. Our core service platforms include: Antibody Drug Discovery Platform, Antibody Engineering Platform, Stable Cell Line Development & Strain Engineering Platform, Recombinant Antibody/Protein Expression & Purification Platform. Beyond technical expertise, KMD Bioscience operates with Integrity, Innovation, and Excellence. Continuous technological innovation fuels our growth, enabling us to deliver optimal solutions to clients.

Tianjin KMD Bioscience Co., Ltd. is a subsidiary of KMD Bioscience (Tianjin) Co., Ltd. Under its leadership, we remain committed to technological innovation and service excellence, striving to lead the industry and contribute to global health.